Dr. Daskivich on Imaging Modalities in Prostate Cancer

Timothy J. Daskivich, MD
Published: Thursday, Mar 01, 2018



Timothy J. Daskivich, MD, assistant professor of surgery, Cedars-Sinai Medical Center, discusses developing and available imaging modalities in prostate cancer.

One of the new cutting-edge techniques for patients with clinically localized prostate cancer is high-intensity focused ultrasound. This has been around the United States since October 2015, and it enables focal treatment of prostate tumors rather than whole-gland treatment. This maximizes cancer control while minimizing morbidity, Daskivich says.

The multi-parametric MRI is an excellent modality for identifying high-grade tumors. It has a 20% miss rate, and Cedars-Sinai Medical Center has developed a platform for high-resolution MRI that improves resolution over multi-parametric MRI by about six-fold, he adds. It identifies 60% of tumors that are invisible to multi-parametric MRI.

PET-MRI is another modality, but it is only available at a handful of centers across the United States; Cedars-Sinai Medical Center is one of them. Ongoing clinical trials are investigating the use of PET tracers like fluciclovine to identify tumors within the prostate gland.
 


Timothy J. Daskivich, MD, assistant professor of surgery, Cedars-Sinai Medical Center, discusses developing and available imaging modalities in prostate cancer.

One of the new cutting-edge techniques for patients with clinically localized prostate cancer is high-intensity focused ultrasound. This has been around the United States since October 2015, and it enables focal treatment of prostate tumors rather than whole-gland treatment. This maximizes cancer control while minimizing morbidity, Daskivich says.

The multi-parametric MRI is an excellent modality for identifying high-grade tumors. It has a 20% miss rate, and Cedars-Sinai Medical Center has developed a platform for high-resolution MRI that improves resolution over multi-parametric MRI by about six-fold, he adds. It identifies 60% of tumors that are invisible to multi-parametric MRI.

PET-MRI is another modality, but it is only available at a handful of centers across the United States; Cedars-Sinai Medical Center is one of them. Ongoing clinical trials are investigating the use of PET tracers like fluciclovine to identify tumors within the prostate gland.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x